Are you Dr. Potter?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 29 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2101 Fm 369 N
Iowa Park, TX 76367Phone+1 940-855-7477- Is this information wrong?
Summary
- Dr. David Potter, DO is a family physician in Iowa Park, Texas. He is currently licensed to practice medicine in Texas.
Education & Training
Creighton University School of Medicine (Omaha)Residency, Family Medicine, 1988 - 1990
Texas College of Osteopathic MedicineClass of 1984
Certifications & Licensure
TX State License 1985 - 2015
Publications & Presentations
PubMed
- Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation.Conway, S. M.,Puttick, D.,Russell, S.,Potter, D.,Roitman, M. F.,Chartoff, E. H.> ;Neuropharmacology. 2018 Dec 12
- Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release.Chartoff, E. H.,Ebner, S. R.,Sparrow, A.,Potter, D.,Baker, P. M.,Ragozzino, M. E.,Roitman, M. F.> ;Neuropsychopharmacology. 2015 Aug 05
- 1 citationsCorrigendum: Adiponectin receptor 1 conserves docosahexaenoic acid and promotes photoreceptor cell survival.Dennis S. Rice, Jorgelina M. Calandria, William C. Gordon, Bokkyoo Jun, Yongdong Zhou, Claire M. Gelfman, Songhua Li, Minghao Jin, Eric J. Knott, Bo Chang, Alex Abuin,...> ;Nature Communications. 2015 May 12
- Join now to see all
Grant Support
- Ocular Hydrodynamics: Modulation By OpioidsNational Eye Institute2002–2004
- Ocular Natriuretic Peptide Activity: Modulation By DrugsNational Eye Institute2002
- Ocular Hydrodynamics: Modulation By OpioidsNational Eye Institute2002
- Ocular Natriuretic Peptide Activity: Modulation By DrugsNational Eye Institute2000–2001
- Ocular Hydrodynamics--Modulation By OpioidsNational Eye Institute1998–2001
- Alpha 2, I1 &Da2 Agonists--Potential Antiglaucoma DrugsNational Eye Institute1994–1997
- Dopamine And A2 Agonists: Potential Antiglaucoma DrugsNational Eye Institute1991–1993
- Dopamine Agonist--Potential Antiglaucoma DrugsNational Eye Institute1989
- Dopamine Agonists: Potential Antiglaucoma DrugsNational Eye Institute1987–1988
- Dopamine Agonist: Potential Antiglaucoma DrugsNational Eye Institute1985–1986
- Dopamine Agonists Potential Antiglaucoma DrugsNational Eye Institute1985
